Studies on plasmepsins I and II from the malarial parasite Plasmodium falciparum and their exploitation as drug targets.
Moon
R P
RP
F. Hoffmann-La Roche, Pharmaceuticals Division, Pharma Research Pre-Clinical, Basel, Switzerland.
Bur
D
D
Loetscher
H
H
D'Arcy
A
A
Tyas
L
L
Oefner
C
C
Grueninger-Leitch
F
F
Mona
D
D
Rupp
K
K
Dorn
A
A
Matile
H
H
Certa
U
U
Berry
C
C
Kay
J
J
Ridley
R G
RG
D000818:Animals; D000962:Antimalarials / Q000494:pharmacology*; D016282:Aspartic Acid Endopeptidases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D010963:Plasmodium falciparum / Q000187:drug effects / Q000201:enzymology* / Q000254:growth & development; D015800:Protozoan Proteins
D000962:Antimalarials; D004791:Enzyme Inhibitors; D006454:Hemoglobins; D015800:Protozoan Proteins; D016282:Aspartic Acid Endopeptidases; C089643:plasmepsin; C100637:plasmepsin II